Mode
Text Size
Log in / Sign up

Narrative review on gut microbiota modulation in Henoch-Schonlein purpura pathogenesisGut bacteria links to Henoch-Schonlein purpura and possible treatments

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that gut microbiota modulation in HSP is an investigational approach with unclear clinical benefit.

This is a narrative review that synthesizes current evidence on the role of gut microbiota dysbiosis in the pathogenesis of Henoch-Schonlein purpura (HSP), also known as immunoglobulin A vasculitis. The scope includes potential therapeutic strategies to modulate the gut microbiota, such as probiotics, prebiotics, traditional Chinese medicine, fecal microbiota transplantation, and targeted-release formulations.

The authors argue that gut microbiota dysbiosis may contribute to HSP pathogenesis, but they do not report pooled effect sizes or specific quantitative findings from primary studies. The review qualitatively discusses the rationale for microbiota modulation as a therapeutic approach.

Key limitations noted by the authors include that the pathogenesis of HSP remains unclear and that evidence for microbiota-based interventions is preliminary. The review does not report a study population, sample size, intervention details, comparator groups, or adverse events.

Practice relevance is not reported, and the authors do not make specific clinical recommendations. The synthesis is cautious, emphasizing the need for further research to establish causality and clinical efficacy.

A new review looks at how the bacteria in our gut might be connected to Henoch-Schonlein purpura (HSP), also called IgA vasculitis. This condition causes inflammation in blood vessels, often leading to a rash, joint pain, and stomach issues. The review suggests that an imbalance in gut bacteria, known as dysbiosis, could play a role in starting or worsening HSP.

The researchers explored several ways to help fix this gut imbalance. These methods include taking probiotics or prebiotics, using traditional Chinese medicine, and even fecal microbiota transplantation (FMT), which transfers healthy gut bacteria from a donor. Other ideas involve special pills that release treatment directly in the gut.

However, the review notes that the exact cause of HSP is still not fully understood. The link to gut bacteria is a promising area for future study, but more research is needed to prove it directly causes the disease. The treatments discussed are still being studied and are not yet standard care.

For patients and doctors, this review highlights a new direction for understanding HSP. It suggests that caring for gut health might one day be part of managing this condition. But currently, the evidence is early, and no specific gut-based treatment is recommended yet.

What this means for you:
Gut bacteria imbalance may be linked to Henoch-Schonlein purpura, with treatments like probiotics being explored.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Henoch–Schönlein purpura (HSP), also known as immunoglobulin A vasculitis, is a common systemic vasculitis in children. Although its pathogenesis remains unclear, recent studies suggest that the gut microbiota may play a significant role in its initiation and progression. In patients with HSP, gut microbiota dysbiosis and associated metabolic alterations are linked to impaired intestinal barrier integrity, activation of the innate immune system, and dysregulation of adaptive immune cell subsets; this includes imbalances in the T helper 17 (Th17)/regulatory T (Treg) and follicular helper T (Tfh)/follicular regulatory T (Tfr) axes. These changes may ultimately trigger immunoglobulin A immune complex deposition and dysregulation of the complement system, potentially establishing a positive feedback loop that drives immune-mediated inflammatory injury. Modulation of the gut microbiota has been shown to restore intestinal barrier function and immune homeostasis; this indicates its potential as a therapeutic target. This review summarizes recent research on gut microbiota alterations in patients with HSP, and evaluates its role in the pathogenesis of the condition. It also discusses promising therapeutic strategies, including probiotics and prebiotics, traditional Chinese medicine and its active components, fecal microbiota transplantation, and targeted-release formulations. This review aims to identify potential microbial biomarkers and therapeutic targets for improving the clinical management of HSP.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.